| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding | |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | Entrez:1489668 - | |
| Gene perturbation-related omics dataset | PerturbAtlas | |||||
| Description | spike glycoprotein | |||||
| GTO ID | GTC2759 |
| Trial ID | NCT05012943 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | ARCT-154|COVID-19 mRNA vaccine, Arcturus |
| Location approved | Japan |
| Phase | Phase2|Phase3 |
| Recruitment status | Completed |
| Title | A Randomized, Observer-Blind, Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the SARS-CoV-2 Self- Amplifying RNA Vaccine ARCT-154 in Adults |
| Year | 2021 |
| Country | Vietnam |
| Company sponsor | Vinbiocare Biotechnology Joint Stock Company |
| Other ID(s) | ARCT-154-01 |
| Vector information | |||
|
|||
| Cohort1: ARCT-154 | |||||||
|
|||||||
| Cohort2: Placebo | |||||||
|
|||||||
| Cohort3: Astra Zeneca COVID-19 vaccine | |||||||
|
|||||||